- Home
- CURV vs NGNE Comparison
CURV vs NGNE Comparison
Compare CURV & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURV
- NGNE
- Stock Information
- Founded
- CURV 2001
- NGNE 2003
- Country
- CURV United States
- NGNE United States
- Employees
- CURV N/A
- NGNE N/A
- Industry
- CURV Clothing/Shoe/Accessory Stores
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- CURV Consumer Discretionary
- NGNE Health Care
- Exchange
- CURV Nasdaq
- NGNE Nasdaq
- Market Cap
- CURV 215.9M
- NGNE 325.3M
- IPO Year
- CURV 2021
- NGNE N/A
- Fundamental
- Price
- CURV $2.16
- NGNE $18.48
- Analyst Decision
- CURV Hold
- NGNE Strong Buy
- Analyst Count
- CURV 4
- NGNE 7
- Target Price
- CURV $4.00
- NGNE $41.86
- AVG Volume (30 Days)
- CURV 482.6K
- NGNE 110.1K
- Earning Date
- CURV 09-04-2025
- NGNE 08-11-2025
- Dividend Yield
- CURV N/A
- NGNE N/A
- EPS Growth
- CURV N/A
- NGNE N/A
- EPS
- CURV 0.09
- NGNE N/A
- Revenue
- CURV $1,089,931,000.00
- NGNE N/A
- Revenue This Year
- CURV N/A
- NGNE N/A
- Revenue Next Year
- CURV N/A
- NGNE N/A
- P/E Ratio
- CURV $24.08
- NGNE N/A
- Revenue Growth
- CURV N/A
- NGNE N/A
- 52 Week Low
- CURV $2.08
- NGNE $6.88
- 52 Week High
- CURV $7.25
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- CURV 35.39
- NGNE 35.93
- Support Level
- CURV $2.13
- NGNE $19.59
- Resistance Level
- CURV $2.24
- NGNE $20.46
- Average True Range (ATR)
- CURV 0.10
- NGNE 1.23
- MACD
- CURV 0.05
- NGNE -0.20
- Stochastic Oscillator
- CURV 38.30
- NGNE 13.37
About CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.